THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy–Innovative Models Prolong Survival (OCTIPS) Consortium

Citation for published version:

Ruscito, I, Cacsire Castillo-tong, D, Vergote, I, Ignat, I, Stanske, M, Vanderstichele, A, Ganapathi, RN, Glajzer, J, Kulbe, H, Trillsch, F, Mustea, A, Kreuzinger, C, Benedetti Panici, P, Gourley, C, Gabra, H, Kessler, M, Sehouli, J, Darb-esfahani, S & Braicu, EI 2017, 'Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy–Innovative Models Prolong Survival (OCTIPS) Consortium', *European Journal of Cancer*, vol. 79, pp. 214-225.
<https://doi.org/10.1016/j.ejca.2017.04.016>

Digital Object Identifier (DOI):

[10.1016/j.ejca.2017.04.016](https://doi.org/10.1016/j.ejca.2017.04.016)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

European Journal of Cancer

Publisher Rights Statement:

This is the authors final peer-reviewed manuscript as accepted for publication.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Exploring the clonal evolution of CD133/ALDH1-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the OCTIPS Consortium.

Ilary RUSCITO^{#1,2,3}, Dan CACSIRE CASTILLO-TONG⁴, Ignace VERGOTE⁵, Iulia IGNAT¹, Mandy STANSKE⁶, Adriaan VANDERSTICHELE⁵, Ram N. GANAPATHI⁷, Jacek GLAJZER¹, Hagen KULBE¹, Fabian TRILLSCH^{8,9}, Alexander MUSTEA¹⁰, Caroline KREUZINGER⁴, Pierluigi BENEDETTI PANICI², Charlie GOURLEY¹¹, Hani GABRA¹², Mirjana KESSLER¹³, Jalid SEHOULI¹, Silvia DARB-ESFAHANI⁶, Elena Ioana BRAICU¹.

1. Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany.

2. Department of Gynecology, Obstetrics and Urology, Sapienza University of Rome, Rome, Italy.

3. Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. ilary.ruscito@uniroma1.it

4. Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

5. Division of Gynaecological Oncology, Leuven Cancer Institute, Department of Gynaecology and Obstetrics, Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, Herestraat 49, B-3000 Leuven, Belgium.

6. Institute of Pathology, Charite Medical University, Berlin, Campus Mitte, Germany.

7. Department of Cancer Pharmacology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.

8. Department of Gynecology and Obstetrics, University of Munich, Marchioninistrasse 15, Munich, Germany.

9. Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Martinistr. 46, Hamburg, Germany.

10. Department of Gynecology and Obstetrics, University Medicine of Greifswald, Greifswald, Germany.

11. Nicola Murray Centre for Ovarian Cancer Research, University of Edinburgh Cancer Research UK Centre, MRC IGMM, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK.

12. Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK.

13. Department of Molecular Biology, Max Planck Institute for Infection Biology, Berlin, Germany.

43 **#Corresponding Author:** Ilary Ruscito, MD
44 Department of Gynecology, European Competence Center for Ovarian Cancer,
45 Campus Virchow Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger
46 Platz 1, D-13353 Berlin, Germany.
47 Phone. +49 (0) 30 450 564 476
48 Fax. +49 (0) 30 450 564 939
49 Email address: ilary.ruscito@uniroma1.it

50

51

52 **Role of the Funding Source**

53 European Community's Seventh Framework Program supported this study under the
54 grant agreement No. 279113-2 (OCTIPS).

55

56

ABSTRACT

Background:High-grade serous ovarian cancer (HGSOC) causes 80% of all OC deaths. In this setting, the role of cancer stem-like cells (CSCs) is still unclear. In particular, the evolution of CSC biomarkers from primary (pOC) to recurrent (rOC) HGSOCs is unknown. Aim of this study was to investigate changes in CD133 and aldehyde dehydrogenase-1(ALDH1) CSC biomarker expression in pOC and rOC HGSOCs.

Methods:224 pOC and rOC intra-patient paired tissue samples derived from 112 HGSOC patients(pts) were evaluated for CD133 and ALDH1 expression using IHC. pOCs and rOCs were compared for CD133 and/or ALDH1 levels. Expression profiles were also correlated with patients' clinico-pathological and survival data.

Results:49.1%(55/112) and 37.5%(42/112) pOCs were CD133+ and ALDH1+, respectively. CD133+ and ALDH1+ samples were detected in 33.9%(38/112) and 36.6%(41/112) rOCs. CD133/ALDH1 coexpression was observed in 23.2%(26/112) and 15.2%(17/112) of pOCs and rOCs, respectively. Pairwise analysis showed a significant shift of CD133 staining from higher (pOCs) to lower expression levels (rOCs)($p<0.0001$). Furthermore, all CD133+pOC pts were FIGO-stage III/IV ($p<0.0001$) and had significantly worse PFI($p=0.04$) and OS($p=0.02$). On multivariate analysis, CD133/ALDH1 coexpression in pOCs was identified as independent prognostic factor for PFI (HR:1.64;95%CI:1.03-2.60; $p=0.036$) and OS (HR:1.71;95%CI:1.01-2.88; $p=0.045$). Analysis on 52 pts with known somatic BRCA status revealed that BRCA mutations did not influence CSC biomarker expression.

Conclusions:The study showed that CD133/ALDH1 expression impacts HGSOC pts' survival and firstly suggests that CSCs might undergo phenotypic change during the

81 disease course similarly to non stem-like cancer cells, providing also a first evidence
82 that there is no correlation between CSCs and BRCA status.

83

84

85 **Key Words:** Ovarian Cancer; CD133; ALDH1; Aldehyde dehydrogenase-1; cancer
86 stem-like cell; BRCA; prognosis; survival.

87

INTRODUCTION

Ovarian cancer (OC) remains the most lethal gynecologic malignancy[1]. Advances in cancer genomics, epigenomics and proteomics has led to the understanding that OC is a heterogeneous group of different tumors displaying distinct phenotypes and etiology[2,3]. The current dichotomous OC classification[4,5] groups these tumors in two distinct categories: Type I (low-grade serous-papillary, low-grade endometrioid, mucinous and clear-cell carcinomas) and Type II (high-grade serous-papillary, high-grade endometrioid, carcinosarcomas and undifferentiated tumors). Type II OCs show a more aggressive biological behavior, are diagnosed at advanced stage and are chromosomally highly unstable. Among them, high-grade serous OC (HGSOC) accounts for around 80% of all OC deaths[3]. The identification of predictive biomarkers is pivotal for designing new treatment strategies able to reduce HGSOC-related mortality. In this context, the cancer stem-like cell (CSC) theory represents one model to investigate OC heterogeneity. This hypothesis, supported by increased evidence acquired in the last decade, proposes that, within OC tissues, a small population of cells has an increased capacity for self-renewal, tumorigenesis and differentiation[6]. In multiple experimental studies CSCs showed to increase potential of tumorigenesis, metastasis/invasion, neoangiogenesis and chemoresistance[7,8] and have been often correlated with a poor prognosis[9-13].

Several potential CSC markers have been identified in OC samples[14-15]. Among them, aldehyde dehydrogenase-1 (ALDH1) and CD133 are currently the best characterized for ovarian CSCs. Their expression on the cell surface is associated with increased tumorigenesis and self-renewal capability [16-18]. Nevertheless, the clonal evolution of CSCs throughout the course of disease, from primary (pOC) to recurrent

(rOC) OC, has not been elucidated yet and information about the changes in CSC presence within the tumor after relapse is still lacking.

The aim of this study was to investigate the evolution of CSC biomarkers CD133 and ALDH1 expression in a large series of paired primary and recurrent HGSOCs.

MATERIALS AND METHODS

Sample Collection

224 paired samples from 112 HGSOC patients were collected during primary and secondary tumor debulking. Patients were included consecutively and have been treated between 1985 and 2013 through primary cytoreduction followed by platinum-based chemotherapy. Patients, retrospectively selected from the OCTIPS (Ovarian Cancer Therapy–Innovative Models Prolong Survival, Agreement No.279113-2) Consortium database, were treated for both pOC and rOC in one of the European Gynecologic Oncology Referral Centers of the following Institutions: Charité Universitätsmedizin Berlin, Germany; Katholieke Universiteit Leuven, Belgium; Imperial College, London, UK; University of Edinburgh, UK.

Inclusion criteria were: having experienced at least one OC relapse for which having been subjected to at least one palliative surgery. Exclusion criterion was: no cancer tissue available from both pOC and rOC. Approval from each local ethics committee was obtained (EK207/2003, ML2524,05/Q0406/178, EK130113,06/S1101/16). OC tissue samples were collected during primary cytoreduction and at the surgery for relapse. All included samples underwent central histopathological assessment to confirm the diagnosis of HGSOC and to evaluate the tissue quality and tumor content.

Immunohistochemistry

Immunohistochemical staining was performed on tissue microarrays (TMAs).

Slides were deparaffinized in xylol, rehydrated in graded alcohol and boiled in a pressure cooker for 5 minutes in citrate buffer (pH=6) for ALDH1 staining or in EDTA (pH=9) for CD133 staining. Mouse anti-human ALDH1-antibody (clone 44;BD Transduction Laboratories, Franklin Lakes, NJ, USA) and mouse anti-human CD133/1-antibody (AC133 clone; Miltenyi-Biotec, Bergisch Gladbach, Germany) were diluted 1:500 and incubated on the slides for 60 minutes at room temperature. Bound antibodies were visualized using DAKO Real Detection System and DAB+ (3,3'-diaminobenzidine; DAKO, Glostrup, Denmark) as a chromogen. Finally, the slides were co-stained with hematoxylin.

CD133 stained samples were assessed basing on the number of stained tumor cells. Samples were classified as “CD133-negative” (<10% CD133 positive tumor cells) and “CD133-positive” (>10% CD133-positive tumor cells) [19-20].

For ALDH1 staining evaluation, as previously published [21-22], the number of stained tumor cells (0%=0; 1-10%=1; 11-50%=2; >50%=3) was multiplied with the intensity of staining (negative=0; weak=1; moderate=2; strong=3), resulting in a semiquantitative immunoreactivity score (IRS) that ranged from 0 to 9. For further analysis, samples were classified “ALDH1-negative”, for absent or weak focal staining (IRS=0-1), or “ALDH1-positive”, for ALDH1-high tumor expression (IRS=2-9).

All samples were evaluated independently by two co-authors (IR and SDE).

Clinical Data and Follow-up

Patients' clinical data and information on 52 patients' germline and/or somatic BRCA status were retrieved from OCTIPS Consortium database [23-24]. Platinum-resistance and platinum-sensitivity were defined, according to GCIG, as relapse occurring before or after six months following the last platinum-based chemotherapy,

respectively[25]. Recurrence was defined basing on RECIST Criteria[26]. A sole CA125 serum elevation was not considered relapse[27].

Statistical Analysis

Statistical analysis was performed using SPSS version 22.0(SPSS Inc, Chicago, IL, USA). To assess the difference between pOCs and rOCs in terms of biomarker expression, the correlation test (Spearman coefficient, 2-tailed) and the “Wilcoxon signed rank” non-parametric test for related samples were applied. Correlation of CD133 and ALDH1 tumor expression with patients’ clinico-pathological categorical data was assessed using the Fisher’s exact test. Patients’ progression-free interval(PFI), progression-free survival (PFS) and overall survival(OS) were determined by Kaplan–Meier analysis (Log-Rank test).PFI represented the time interval from the last adjuvant chemotherapy to relapse, whereas progression-free survival (PFS) was the time interval between first recurrence diagnosis and tumor progression. For univariate and multivariate survival analyses, the Cox regression model was used. Multivariable models were performed among variables reporting a p-value $\leq$ 0.1 in univariate analysis. P values $\leq$ 0.05 were considered statistically significant.

RESULTS

Primary and recurrent intra-patient paired tumor samples derived from 112 HGSOc patients were analyzed for CD133 and ALDH1 expression. Patients’ characteristics are listed in **Table 1**.

Immunohistochemistry staining showed that ALDH1 and CD133 proteins were localized to the cytoplasm(**Fig1, Fig.3**).

CD133 expression.

CD133-positive (CD133⁺) staining was significantly more frequent among pOCs[55/112(49.1%)] compared to rOCs[38/112(33.9%)], $p=0.030$ (Fisher's exact test,**Fig.1a,1c**). Investigation of sequential changes in CD133⁺ expression in paired tumors, with a correlation test (Spearman coefficient) between pOCs and rOCs, demonstrated a significant correlation ($p=0.001$,Spearman coefficient 0.306). Furthermore, pairwise testing revealed a significant shift from higher frequency of CD133⁺ cells in pOCs to lower levels in the paired recurrent samples ($p<0.0001$, Wilcoxon test;**Fig.2**), thus indicating significantly higher rates of CD133⁺ cells in pOCs compared to rOCs.

ALDH1 expression.

Distribution of ALDH1 IRS in pOCs and rOCs is shown in **Fig.3a,3d**. ALDH-1 positive tumors were found in 37.5%(42/112) and 36.6%(41/112) of primary and recurrent samples, respectively ($p=1$,Fisher's exact test,**Fig.3b,3e**). A trend for significant correlation between pOCs and rOCs ALDH1-expression levels was seen ($p=0.059$,Spearman coefficient 0.179). Pairwise analysis showed no tendency towards a change of IRS values to higher or lower levels in recurrences ($p=0.988$,Wilcoxon test;**Fig.4**).

CD133/ALDH1 co-expression.

Co-expression of both CSCs biomarkers was detected in 23.2%(26/112) of pOCs and in 15.2%(17/112) of rOCs($p=0.174$,Fisher's exact test). Among 26 patients reporting CD133/ALDH1 co-expression in pOCs, 22(84.6%) lost this pathological characteristic in relapse situation. Of the 17 patients presenting biomarker co-expression in rOC, 13(76.5%) showed no co-expression in pOC. Consequently, 4/112

patients (3.6%) showed CD133/ALDH1 co-expression in both pOC and rOC: two of them were platinum-resistant and two were platinum-sensitive.

CSCs biomarkers and clinico-pathological factors

We analyzed the correlation of ALDH1 and/or CD133 tumor expression patterns in pOCs with patients' clinico-pathological characteristics. All primary CD133⁺ patients were diagnosed at FIGO III/IV stage (p=0.006). No correlation was observed between other clinico-pathological factors and ALDH1 and/or CD133 tumor expression(**Tab.2**).

Survival

CD133 positivity in pOCs was significantly associated with poor PFI and OS (**Fig.5a,5b**). In particular, CD133⁺ and CD133⁻ patients reported median OS of 51 and 71 months (HR:1.713;95%CI:1.076-2.727;p=0.02) and median PFI of 9 and 17 months (HR:1.477;95%CI:1.006-2.170;p=0.04). PFS after recurrence was not significantly different (p=0.868,**Fig.5c**) between patients with CD133⁺ and CD133⁻ or between (p=0.252,**Fig.5f**) patients with ALDH1⁺ and ALDH1⁻OC.

Median OS for ALDH1⁺ and ALDH1⁻ patients was 52 and 64 months, respectively (p=0.402) and median PFI-1 was 9 and 17 months, respectively (p=0.199)(**Fig.5d,5e**).

ALDH1/CD133 co-expression in pOCs was found to significantly affect HGSOc patients' outcome. A significant decrease in OS and PFI has been found in patients co-expressing ALDH1/CD133 in primary tissue (46 and 9 months, respectively) compared to patients without biomarker co-expression (68 and 17 months, respectively) (p=0.019,**Fig.5g**;p=0.015,**Fig.5h**). No significant difference in PFS after relapse was observed between patients who reported CD133/ALDH1 co-expression or no co-expression in rOC(p=0.898,**Fig.5i**).

On multivariate analysis, the co-expression of ALDH1 and CD133 in pOC, rather than the single expression of one biomarker, was identified to be an independent prognostic factor for both PFI (HR:1.638;95%CI:1.033-2.598;p=0.036) and OS (HR:1.707;95%CI:1.012-2.881;p=0.045) in HGSOc(Tab.3,4).

Outliers' sub-analysis

“Outliers” were considered patients for whom the highest difference between pOC and rOC could be detected in CD133+cell rate. Three patients were identified: two reported a difference in CD133+cell rate of -90%(from 90% of CD133+cells at pOC to 0% at rOC); the first one was a platinum-resistant patient with PFI of 2 months and OS of 14 months; the second one was a platinum-sensitive patient with PFI of 7 months and OS of 9 months. The third patient showed a difference in CD133+cell rate of +70%(from 0% of CD133+ at pOC cells to 70% in rOC) with PFI of 15 months (platinum-sensitive) and OS of 44 months.

CSC biomarker expression and BRCA status

In order to investigate if BRCA mutations could influence CSC biomarker expression, a subgroup analysis was carried out among 52 patients, whose germline and/or somatic BRCA status (assessed on pOC and rOC) was available [24]. 40.4% of tested patients (21/52) had a somatic BRCA mutation in both pOCs and rOCs: 16/52(30.8%) were BRCA1-mutated (mBRCA1) and 5/52(9.6%) were BRCA2-mutated (mBRCA2)(Tab.5).

No significant difference in CD133 and/or ALDH1 expression was found between BRCA-wild type (BRCA-WT) and BRCA-mutant (mBRCA1/2) tumors(Tab.6).

Among BRCA-WT patients, no correlation between pOCs and rOCs in CD133+ expression was observed (p=0.088,Spearman coefficient 0.312). Furthermore, in accordance with results observed in the whole population, paired testing revealed a

significant shift from higher levels in pOCs to lower levels in the rOCs ($p < 0.0001$, Wilcoxon test; **Fig. 6a**). In contrast, among mBRCA1/2 patients, no correlation between pOCs and rOCs ($p = 0.493$, Spearman coefficient 0.158), or a tendency towards a change in CD133+ expression was observed ($p = 0.167$, Wilcoxon test; **Fig. 6b**).

Regarding ALDH1 expression, among BRCA-WT patients no correlation between pOCs and rOCs in ALDH1 IRS was found ($p = 0.986$, Spearman coefficient 0.003), as well as no change in paired testing ($p = 0.895$, Wilcoxon test; **Fig. 7a**); also for mBRCA1/2 patients no difference was observed in ALDH1-IRS between primary and recurrent patients ($p = 0.410$, Spearman coefficient 0.190; $p = 0.385$, Wilcoxon test; **Fig. 7b**).

Among BRCA-WT patients, only 1/31 patient (3.2%) showed CD133/ALDH1 co-expression in both pOCs and rOCs. In 3/31 (9.7%) patients the co-expression was evidenced in rOCs but not in pOCs. 90% of patients (9/10) reporting CD133/ALDH1 co-expression in pOC lost biomarker co-expression at tumor relapse.

Also for mBRCA1/2 patients, only 1/21 (4.8%) patient showed CD133/ALDH1 co-expression in both pOC and rOC. Two patients (9.5%) had co-expression at recurrent rather than at primary disease. The difference between BRCA-WT and mBRCA1/2 patients in terms of co-expression loss at rOC was not significant (4/5 vs 9/10, $p = 1$, Fisher's exact test).

Considering patients who were CD133+ and/or ALDH1+ at pOC, no significant difference could be detected in PFI and OS among BRCA-WT vs mBRCA1/2 cases (**Fig. 8**).

DISCUSSION

286 In the Era of Precision Medicine, huge steps have been taken in the understanding of
287 HGSOC biology. In this tumor setting, the role of CSC and its clonal evolution during
288 subsequent disease relapse has been relatively unexplored.

289 This study investigated the changes in CSC biomarkers CD133 and ALDH1
290 expression in primary and recurrent HGSOCs and showed that CD133+CSCs are
291 significantly more represented in pOCs rather than rOCs, whereas no significant
292 changes in terms of ALDH1 expression levels occurred at disease relapse.

293 Furthermore, CD133 positivity in pOCs significantly correlates with poor survival,
294 while co-expression of both CD133 and ALDH1 in primary samples independently
295 predicted poor PFI and OS in HGSOC patients.

296 In 2015, Zhou published a meta-analysis[28], which investigated the prognostic value
297 of immunohistochemical CD133 expression in OC. Pooled data derived from 1050
298 patients from 8 studies showed that CD133 positivity significantly correlates with
299 advanced FIGO stage at diagnosis and with worse OS, in accordance with our
300 findings, although our population was restricted to HGSOC.

301 Other recent meta-analysis demonstrated that also ALDH1 is a promising prognostic
302 biomarker for breast[9], head/neck[10], lung[11]and colorectal cancer[12] but its
303 predictive or prognostic role in OC is still controversial[13,29-31]. In contrast to
304 CD133, ALDH1 expression is usually low or negative in serous OC compared to
305 other cancer histotype and more frequent in low FIGO stage tumors[13,29].

306 Previously, Liebscher[21] investigated the prognostic impact of ALDH1 expression
307 in a homogeneous group of primary HGSOC patients and demonstrated that ALDH1
308 was an independent prognostic factor for OS. These results differ from our findings,
309 since in our population ALDH1 did not have an impact on patients' survival.

310 Nevertheless, in Liebscher's population the frequency of FIGO Stage I-II cases was

higher than in our population (11.5% vs 7.2%), while the number of optimally cytoreduced patients was lower (66.3% vs 80.4%).

Silva[32] showed that the co-expression of CD133 and ALDH1 correlated with significant worse PFI and OS in a small cohort of 56 ovarian cancer patients. These results were in accordance with our findings in a larger HGSOc population.

To our knowledge, this is the first study analyzing the evolution of CSC markers in the largest cohort of primary and recurrent HGSOc patients. Furthermore, the subanalysis on patients with known BRCA status increases the value of the findings by taking into consideration the genetic influence of BRCA status on patients' survival[33-34] and provides a first evidence of the correlation between tumor-initiating cells and homologous recombination deficiency. Limitation of the study was the lack of information regarding BRCA1/2 status on all enrolled patients. The analysis on a cohort of 52 patients could not provide definitive conclusions for this issue.

Interestingly, we observed that 84.6% of our patients' cohort reporting CD133/ALDH1 co-expression in pOC lost this pathological characteristic at relapse. Nevertheless, while CSC biomarker expression is significantly correlated with poor prognosis, it is enigmatic why in a recurrent setting, which represents a more aggressive step of the disease compared to primary disease, CSCs are less frequently encountered. Theoretically, CSCs were expected to be much more frequent in rOC than in the pOC. We hypothesize that the reduction in CSC biomarker expression does not represent a reduction in CSC number within the tumor sample, but might be the result of cellular reprogramming occurring in the CSC itself, which might lead to the loss of CSC biomarker expression. Studies on this issue are still lacking.

This study shows that CD133 and ALDH1 as biomarkers can have influence on HGSOC patients' survival and for the first time suggests that they might be caused by a phenotypical change during the course of the disease similarly to non stem-like cancer cells. However, the need for recurrent tumor tissue to be analyzed implied that this cohort of samples might be not the most representative one for ovarian cancer patients, due to the fact that most of patients had a platinum sensitive relapse, and surgical approach at relapse was feasible. For this reason, general conclusion for the whole recurrent ovarian cancer setting cannot currently be drawn.

Another limitation of the study is that these biomarkers, in particular ALDH1, are broadly expressed, not only by CSCs. The identification of CSC is actually sure only based on the capacity to build spheroids, on tumor xenograft assay and on serial transplantation assay, which require fresh tumor tissue. Nevertheless, IHC allowed to analyze a large cohort of paired tumor tissues and to observe that there is a change in CSC-associated biomarker expression between primary and relapse disease.

Further investigations on larger cohort of paired pOC and rOC samples are warranted, potentially expanding the scope with inclusion of further candidate CSC markers and with evaluation of CSCs behavior following neoadjuvant chemotherapy[31,35-36], in order to reduce mortality of one of the most deadly malignancies of our time.

Acknowledgements.

This work was supported by European Community's Seventh Framework Program under grant agreement No. 279113-2 (OCTIPS). The documentation of clinical and patient's data was managed with "AlcedisTRIAL the web based documentation system" of Alcedis GmbH, Winchesterstr. 3, 35394 Giessen, Germany.

359 Elena Ioana Braicu, MD, PhD is participant in the BIH Charité Clinician Scientist
360 Program funded by the Charité Universitätsmedizin Berlin and the Berlin Institute of
361 Health.

362 **Role of the Funding Source**

363 European Community's Seventh Framework Program supported this study under the
364 grant agreement No. 279113-2 (OCTIPS).

365

366 **Conflict of interest statement.**

367 All Authors declare no conflict of interest.

REFERENCES

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer*. 2013;49:1374-403.
2. Vaughan S, Coward JJ, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. *Nat Rev Cancer*. 2011;11:719-25.
3. Network CGAR: Integrated genomic analyses of ovarian carcinoma. *Nature* 2011;474:609-15.
4. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. *J Clin Oncol*. 2008;26:5284-93.
5. Li J, Fadare O, Xiang L, Kong B, Zheng W. Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. *J Hematol Oncol*. 2012; 5:8.
6. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature*. 1994;367:645-8.
7. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. *Cancer Cell*. 2012;21:283-96
8. Foster R, Buckanovich RJ, Rueda BR. Ovarian cancer stem cells: working towards the root of stemness. *Cancer Lett*. 2013;338:147-57.
9. Liu Y, Lv DL, Duan JJ, Xu SL, Zhang JF, Yang XJ, et al. ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis. *BMC Cancer*. 2014;14:444.
10. Zhou C, Sun B. The prognostic role of the cancer stem cell marker aldehyde dehydrogenase 1 in head and neck squamous cell carcinomas: a meta-analysis. *Oral Oncol*. 2014;50:1144-8.
11. Wei D, Peng JJ, Gao H, Zhang T, Tan Y, Hu YH. ALDH1 Expression and the Prognosis of Lung Cancer: A Systematic Review and Meta-Analysis. *Heart Lung Circ*. 2015;24:780-8.
12. Chen J, Xia Q, Jiang B, Chang W, Yuan W, Ma Z, et al. Prognostic Value of Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. *PLoS One*. 2015;10:e0145164.
13. Huang R, Li X, Holm R, Trope CG, Nesland JM, Suo Z. The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study. *BMC Cancer*. 2015;15:502.

14. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor- like cells contribute to the aggressive behavior of human epithelial ovarian cancer. *Cancer Res* 2005;65:3025-9.
15. Chen X, Zhang J, Zhang Z, Li H, Cheng W, Liu J. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. *Human Pathol* 2013, 44(11): 2373–2384;
16. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. *Oncogene* 2009;28:209-18.
17. Kuroda T, Hirohashi Y, Torigoe T, Yasuda K, Takahashi A, Asanuma H et al. ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis. *PLoS One*. 2013, 8(6): e65158;
18. Curley MD, Therrien VA, Cummings CL, Sargent PA, Koulouris CR, Friel AM et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. *Stem Cells* 2009, 27:2875–2883
19. HZ L, YS B, WW L and RY L. Expression and clinical significance of CD133 and Notch1 gene in epithelial ovarian carcinoma. *Chin J Clinicians (Electronics Edition)* 2012; 6: 2086-8.
20. Qin Q, Sun Y, Fei M, Zhang J, Jia Y, Gu M, et al. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer. *Neoplasma* 2012; 59: 310-5.
21. Liebscher CA, Prinzler J, Sinn BV, Budczies J, Denkert C, Noske A, et al. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma. *Hum Pathol*. 2013;44:1465-71.
22. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. *Cancer Res*. 2009;69:3382-9.
23. Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, et al. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. *Eur J Cancer*. 2016;53:51-64.
24. Patel JN, Sehouli J, Timms K, Solimeno C, Reid EJ, Lanchbury JS, et al. Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC). *J Clin Oncol* 33, 2015 (suppl; abstr 5534).
25. Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M et al. Clinical trials in recurrent ovarian cancer. *Int J Gynecol Cancer*. 2011;21:771-5.

26. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *European Journal of Cancer* 2009; 45:228-247.
27. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). *Int J Gynecol Cancer*. 2011;21:419-23.
28. Zhou Q, Chen A, Song H, Tao J, Yang H, Zuo M. Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis. *Int J Clin Exp Med*. 2015;8:3080-8.
29. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, et al. ALDH1 expression correlates with favorable prognosis in ovarian cancers. *Mod Pathol*. 2009;22:817-23.
30. Chen PX, Li QY, Yang Z. Musashi-1 Expression is a Prognostic Factor in Ovarian Adenocarcinoma and Correlates with ALDH-1 Expression. *Pathol Oncol Res*. 2015;21:1133-40.
31. Ayub TH, Keyver-Paik MD, Debald M, Rostamzadeh B, Thiesler T, Schröder L, et al. Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer. *Oncotarget*. 2015;6:16437-48.
32. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. *Cancer Res*. 2011;71:3991-4001.
33. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. *JAMA*, 2011. 306:1557-65.
34. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. *JAMA*, 2012. 307:382-9.
35. Xu ZY, Tang JN, Xie HX, Du YA, Huang L, Yu PF, et al. 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells. *Int J Biol Sci*. 2015;11:284-94.
36. Mizukami T, Kamachi H, Mitsuhashi T, Tsuruga Y, Hatanaka Y, Kamiyama T, et al. Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy. *BMC Cancer*. 2014;14:687.

LEGEND TO TABLES AND FIGURES

- Table 1: Patients' characteristics
- Table 2: Association of CSCs biomarkers expression with patients' clinico-pathological characteristics (primary tumors).
- Table 3: Multivariate analysis for PFI
- Table 4: Multivariate analysis for OS
- Table 5: patients' germline and/or somatic (primary and recurrent tumor) BRCA status.
- Table 6: Association of CSCs biomarkers expression with patients' BRCA status (primary tumors).
- Figure 1: CD133 immunohistochemistry staining. Primary tumors, CD133+ (a) and CD133- (b) samples; recurrent tumors, CD133+ (c) and CD133- (d) samples.
- Figure 2: CD133+ cell rates among primary and recurrent tumors (box plot – a - and line plot – b).
- Figure 3: ALDH1 immunohistochemistry staining. ALDH1 IRS at primary (a) and recurrent (d) tumors. Primary tumors, ALDH1+ (b) and ALDH1- (c) samples; recurrent tumors, ALDH1+ (e) and ALDH1- (f) samples.
- Figure 4: ALDH1 IRS among primary and recurrent tumors (box plot – a - and line plot – b).
- Figure 5: CD133 and/or ALDH1 status in primary (a, b, d, e, g, h) and recurrent (c, f, i) samples and survival.
- Figure 6: CD133+ cell rates among primary and recurrent tumors (box plot, BRCA-WT- a - and box plot mBRCA1/2 – b).
- Figure 7: ALDH1 IRS among primary and recurrent tumors (box plot BRCA-WT- a - and box plot mBRCA1/2 – b).
- Figure 8: CD133+ and/or ALDH1+ and survival in BRCA-WT and mBRCA1/2 patients (primary tumors).

Figure 1

a

b

c

d

Figure 2

a

b

Figure 3

a

ALDH1 IRS primary

b

c

d

ALDH1 IRS recurrent

e

f

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Table 1

PARAMETER	
PATIENTS (n.)	112
AGE Median (range)	56y (33-77y)
FIGO STAGE (%)	
- I	2 (1.8%)
- II	6 (5.4%)
- III	93 (83%)
- IV	11 (9.8%)
RESIDUAL TUMOR AFTER PRIMARY DEBULKING SURGERY:	
- No residual tumor	90 (80.4%)
- Residual Tumor	22 (19.6%)
PLATINUM SENSITIVITY STATUS AFTER PRIMARY TREATMENT	
- Platinum sensitive	90 (80.4%)
- Platinum resistant	18 (16.1%)
- Missing	4 (3.5%)
PLATINUM SENSITIVITY STATUS AFTER TREATMENT FOR DISEASE RELAPSE	
- Platinum sensitive	59 (52.7%)
- Platinum resistant	12 (10.7%)
- Missing	41(36.6%)

Table 2

Clinico-pathological factors	Total N°	CD133			ALDH1			CD133 and ALDH1 coexpression		
		Positive (%)	Negative (%)	P	Positive (%)	Negative (%)	P	Positive (%)	Negative (%)	P
Patients' Age										
< 56y	54	27 (50%)	27 (50%)	0.855	18 (33%)	36 (67%)	0.288	11 (20%)	43 (80%)	0.492
≥ 56y	58	28 (48%)	30 (52%)		25 (43%)	33 (57%)		15 (26%)	43 (74%)	
FIGO STAGE										
I/II	8	0	8 (100%)	0.006	3 (38%)	5 (62%)	1.000	0	8 (100%)	0.194
III/IV	104	55 (53%)	49 (47%)		40 (39%)	64 (61%)		26 (25%)	78 (75%)	
RESIDUAL TUMOR AFTER FIRST CYTOREDUCTIVE SURGERY										
No residual	90	42 (47%)	48 (53%)	0.346	35 (39%)	55 (61%)	1.000	20 (22%)	70 (78%)	0.586
Any residual	22	13 (59%)	9 (41%)		8 (36%)	14 (64%)		6 (27%)	16 (73%)	
PLATINUM SENSITIVITY STATUS AFTER PRIMARY TREATMENT										
Platinum sensitive	90	43 (48%)	47 (52%)	0.439	33 (37%)	57 (63%)	0.303	19 (21%)	71 (79%)	0.357
Platinum resistant	18	7 (39%)	11 (61%)		9 (50%)	9 (50%)		6 (33%)	12 (67%)	

Table 3

PROGRESSION FREE INTERVAL

	UNIVARIATE ANALYSIS		MULTIVARIATE ANALYSIS	
	HR (95% CI)	P	HR (95% CI)	P
Age	1.003 (0.983-1.024)	0.774		
FIGO Stage (III/IV vs I/II)	2.019 (0.907-4.496)	0.085	1.856 (0.826-4.169)	0.134
Residual Tumor (any residual vs no residual)	1.026 (0.625-1.684)	0.919		
CD133/ALDH1 coexpression (positive vs negative)	1.729 (1.093-2.733)	0.019	1.638 (1.033-2.598)	0.036

Table 4

OVERALL SURVIVAL

	UNIVARIATE ANALYSIS		MULTIVARIATE ANALYSIS	
	HR (95% CI)	P	HR (95% CI)	P
Age	1.011 (0.985-1.038)	0.404		
FIGO Stage (III/IV vs I/II)	1.465 (0.533-4.020)	0.459		
Residual Tumor (any residual vs no residual)	1.632 (0.973-2.736)	0.063	1.272 (0.725-2.231)	0.401
Platinum sensitivity status after primary treatment (platinum resistant vs platinum sensitive)	3.394 (1.927-5.978)	<0.001	2.907 (1.594-5.302)	<0.001
CD133/ALDH1 coexpression (positive vs negative)	1.799 (1.089-2.971)	0.022	1.707 (1.012-2.881)	0.045

Table 5

PATIENT ID	GERMLINE BRCA STATUS	SOMATIC BRCA STATUS – PRIMARY TUMOR	SOMATIC BRCA STATUS – RECURRENT TUMOR
B001	mBRCA1	mBRCA1	mBRCA1
B002	WT	WT	WT
B003	WT	WT	WT
B006	N/A	WT	WT
B007	N/A	WT	WT
B009	N/A	WT	WT
B012	N/A	WT	WT
B015	N/A	WT	WT
B019	WT	mBRCA2	mBRCA2
B021	N/A	WT	WT
B022	N/A	WT	WT
B024	mBRCA1	mBRCA1	mBRCA1
B025	N/A	WT	WT
B026	N/A	WT	WT
B028	mBRCA1	mBRCA1	mBRCA1
B029	mBRCA1	mBRCA1	mBRCA1
B030	N/A	WT	WT
B032	WT	WT	WT
B037	N/A	WT	WT
B041	mBRCA1	mBRCA1	mBRCA1
B044	N/A	WT	WT
B045	N/A	mBRCA1	mBRCA1
B048	WT	WT	WT
B050	WT	WT	WT
B051	N/A	mBRCA2	mBRCA2
B052	WT	WT	WT
B053	N/A	WT	WT
B054	N/A	WT	WT
B062	N/A	WT	WT
B063	N/A	mBRCA2	mBRCA2
B065	WT	WT	WT
B068	N/A	mBRCA1	mBRCA1
B069	N/A	WT	WT
B071	N/A	mBRCA1	mBRCA1
B077	mBRCA2	mBRCA2	mBRCA2
B080	mBRCA2	mBRCA2	mBRCA2
B081	WT	mBRCA1	mBRCA1
B082	N/A	mBRCA1	mBRCA1
B085	N/A	mBRCA1	mBRCA1
B087	mBRCA1	mBRCA1	mBRCA1
B088	N/A	WT	WT
B090	N/A	mBRCA1	mBRCA1
B093	N/A	WT	WT
B094	N/A	mBRCA1	mBRCA1
B097	N/A	mBRCA1	mBRCA1
B098	N/A	WT	WT
B099	N/A	WT	WT
B100	N/A	WT	WT
L007	WT	WT	WT
L010	WT	WT	WT
L017	WT	WT	WT
L020	mBRCA1	mBRCA1	mBRCA1

Table 6

BRCA status	Total N°	CD133			ALDH1			CD133 and ALDH1 coexpression		
		Positive (%)	Negative (%)	P	Positive (%)	Negative (%)	P	Positive (%)	Negative (%)	P
BRCA-WT	31	21 (68%)	10 (32%)	0.769	13 (42%)	18 (58%)	0.575	10 (32%)	21 (68%)	0.551
mBRCA1/2	21	13 (62%)	8 (38%)		7 (33%)	14 (67%)		5 (24%)	16 (76%)	